Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ activating capacity: effects on platelet indices associated with cardiovascular disease

Christos Rizos, Evangelos Liberopoulos, Stavroula Tsiara, Moses Elisaf



Introduction: Platelets play an important role in atherosclerosis development and progression. Various platelet indices have been associated with cardiovascular disease risk. The effect of combined treatment with a potent statin plus angiotensin receptor inhibitors with different PPARγ activating capacity is unknown.
Methods: Patients (n=151) with hypertension, dyslipidemia and impaired fasting glucose were randomly allocated to rosuvastatin (10 mg/day) plus telmisartan 80 mg/day (RT group, n=52) or irbesartan 300 mg/day (RI group, n=48) or olmesartan 20 mg/day (RO group, n=51). After 6 months of treatment, changes in common platelet indices were evaluated.
Results: After 6 months of treatment, platelet count, mean platelet volume, platelet distribution width and platelet larger cell ratio remained unchanged in all groups. Moreover, no difference between groups was observed.
Conclusions: The combination of rosuvastatin with sartans of different PPARγ activating capacity was not associated with any changes in common platelet indices.

Keywords: rosuvastatin, telmisartan, olmesartan, irbesartan, platelets, cardiovascular disease